Concepedia

Thomas Markotan

TM

Statistics

Publications

8

Citations

204

H-Index

8

Active since

1999

Affiliations

Johnson & Johnson (United States)(Current)

Springhouse

Thomas Markotan is an author at Johnson & Johnson (United States) specializing in drug discovery, medicinal chemistry, and pharmacology.

Publications per year

1999–2018

8

Publications

8

7-Fluoroindazoles as Potent and Selective Inhibitors of Factor Xa

Yu‐Kai Lee, Daniel J. Parks, Tianbao Lu et al. · Journal of Medicinal Chemistry · 2007 · 55 citations · Full text

, , +9

Discovery and Clinical Evaluation of 1-{<i>N</i>-[2-(Amidinoaminooxy)ethyl]amino}carbonylmethyl-6-methyl-3-[2,2-difluoro-2-phenylethylamino]pyrazinone (RWJ-671818), a Thrombin Inhibitor with an Oxyguanidine P1 Motif

Tianbao Lu, Thomas Markotan, Shelley K. Ballentine et al. · Journal of Medicinal Chemistry · 2010 · 34 citations · Full text

, , +17

Oxyguanidines. Part 2: Discovery of a novel orally active thrombin inhibitor through structure-based drug design and parallel synthesis

Tianbao Lu, Thomas Markotan, Frank T. Coppo et al. · Bioorganic & Medicinal Chemistry Letters · 2004 · 25 citations · Full text

, , +14

A novel series of N-(azetidin-3-yl)-2-(heteroarylamino)acetamide CCR2 antagonists

Nalin L. Subasinghe, James C. Lanter, Thomas Markotan et al. · Bioorganic & Medicinal Chemistry Letters · 2012 · 21 citations · Full text

, , +4

Antibody drug conjugates of cleavable amino-alkyl and aryl maytansinoids

Thomas Nittoli, Marcus P. Kelly, Frank J. Delfino et al. · Bioorganic & Medicinal Chemistry · 2018 · 21 citations

, , +14

1–5 of 8